Metabolic markers and HSP60 in chemonaive serous solid ovarian cancer versus ascites

International Journal of Gynecological Cancer

Volumn 24, Issue 8, 2014, Pages 1389-1394

  Hjerpe, Elisabet ^a   Brage, Suzanne Egyhazi ^a   Stolt, Marianne Frostvik ^a   Johansson, Hemming ^a   Shoshan, Maria ^a   Åvall Lundqvist, Elisabeth ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Ascites; Metabolic markers; mRNA; Serous ovarian cancer

Indexed keywords

BIOLOGICAL MARKER; CHAPERONIN 60; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; MITOCHONDRIAL BETA F1 ADENOSINE TRIPHOSPHATASE; MITOCHONDRIAL PROTEIN; PYRUVATE KINASE; PYRUVATE KINASE ISOFORM M2; UNCLASSIFIED DRUG; ATP5B PROTEIN, HUMAN; CARRIER PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE (NADP)(PHOSPHORYLATING); HSPD1 PROTEIN, HUMAN; MEMBRANE PROTEIN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; THYROID HORMONE; THYROID HORMONE-BINDING PROTEINS; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CELL; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HUMAN; MALIGNANT ASCITES; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SEROUS SOLID OVARIAN CANCER; SOLID TUMOR; ADJUVANT THERAPY; ASCITES; CYSTADENOCARCINOMA; GENETICS; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY;

AGED; ASCITES; CARRIER PROTEINS; CHAPERONIN 60; CYSTADENOCARCINOMA, SEROUS; FEMALE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE (NADP+)(PHOSPHORYLATING); HUMANS; MEMBRANE PROTEINS; METABOLIC NETWORKS AND PATHWAYS; MIDDLE AGED; MITOCHONDRIAL PROTEINS; MITOCHONDRIAL PROTON-TRANSLOCATING ATPASES; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; THYROID HORMONES; TUMOR MARKERS, BIOLOGICAL;

EID: 84925592535     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000246     Document Type: Article

References (20)

1. Heintz APM, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. Int J Gynaecol Obstet. 2006;95:S161-S192.
2. Davidson B. Anatomic site-related expression of cancer-associated molecules in ovarian carcinoma. Curr Cancer Drug Targets. 2007;7:109-120.
3. Jose C, Bellance N, Rossignol R. Choosing between glycolysis and oxidative phosphorylation: a tumor's dilemma? Biochim Biophys Acta. 2011;1807:552-561.
4. Smolková K, Plecitá-Hlavatá L, Bellance N, et al. Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. Int J Biochem Cell Biol. 2011;43:950-968.
5. Hjerpe E, Egyhazi Brage S, Carlson J, et al. Metabolic markers GAPDH, PKM2, ATP5B, and BEC-index in advanced serous ovarian cancer. BMC Clin Pathol. 2013;13:30.
6. Hjerpe E, Egyhazi S, Carlson J, et al. HSP60 predicts survival in advanced serous ovarian cancer. Int J Gynecol Cancer. 2013;23:448-455.
7. Tavassoé li F, Devilee P, eds. WHO Classification of Tumours. Lyon, France: IARC Press; 2003.
8. Bjorge L, Hakulinen J, Vintermyr OK, et al. Ascitic complement system in ovarian cancer. Br J Cancer. 2005;92:895-905.
9. Jose C, Rossignol R. Rationale for mitochondria-targeting strategies in cancer bioenergetic therapies. Int J Biochem Cell Biol. 2013;45:123-129.
10. Kipps E, Tan DSP, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13:273-282.
11. Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology. 1988;8:1104-1109.
12. Cichon MA, Radisky DC. Separation anxiety: detachment from the extracellular matrix induces metabolic changes that can stimulate tumorigenesis. J Mol Cell Biol. 2010;2:113-115.
13. Danhier P, Copetti T, De Preter G, et al. Influence of cell detachment on the respiration rate of tumor and endothelial cells. PLoS One. 2013;8:e53324.
14. Wintzell M, Hjerpe E, Avall Lundqvist E, et al. Protein markers of cancer-associated fibroblasts and tumor-initiating cells reveal subpopulations in freshly isolated ovarian cancer ascites. BMC Cancer. 2012;12:359.
15. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11-20.
16. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029-1033.
17. Lee SY, Jeon HM, Ju MK, et al. Wnt/Snail signaling regulates cytochrome c oxidase and glucose metabolism. Cancer Res. 2012;72:3607-3617.
18. Ahmed N, Thompson EW, Quinn MA. Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. J Cell Physiol. 2007;213:581-588.
19. Huang RY-J, Chung VY, Thiery JP. Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer. Curr Drug Targets. 2012;13:1649-1653.
20. Willers IM, Cuezva JM. Post-transcriptional regulation of the mitochondrial H + - ATP synthase: a key regulator of the metabolic phenotype in cancer. Biochim Biophys Acta. 2011;1807:543-551.